G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

Journal of Medicinal Chemistry

Volumn 59, Issue 8, 2016, Pages 3579-3592

  Ritter, Kurt ^a   Buning, Christian ^a   Halland, Nis ^a   Pöverlein, Christoph ^a   Schwink, Lothar ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AR 231453; G PROTEIN COUPLED RECEPTOR 119 AGONIST; GLUCOSE; GSK 1104252A; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; GPR119 PROTEIN, HUMAN; LIGAND;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG INDUSTRY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; EMBRYO; ENTEROENDOCRINE CELL; GLUCOSE BLOOD LEVEL; HEK293 CELL LINE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; HYPOGLYCEMIA; INSULIN RELEASE; INTRINSIC ACTIVITY; MALE; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL CHEMISTRY; RAT; REVIEW; AGONISTS; CLINICAL TRIAL (TOPIC); METABOLISM;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84966936702     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01198     Document Type: Review

References (81)

1. Diabetes Fact Sheets No. 312; World Health Organization (WHO): Geneva, 2013; http://www.who.int/mediacentre/factsheets/fs312/en/.
2. National Diabetes Statistics Report, 2014; Center for Disease Control and Prevention (CD): Atlanta, 2014; http://www.cdc.gov/diabetes/pubs/statsreport14.htm.
3. Lorenz, M.; Evers, A.; Wagner, M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity Bioorg. Med. Chem. Lett. 2013, 23, 4011-4018 10.1016/j.bmcl.2013.05.022
4. Albrechtsen, N. J. W.; Kuhre, R. E.; Deacon, C. F.; Holst, J. J. Targeting the intestinal L-cell for obesity and type 2 diabetes treatment Expert Rev. Endocrinol. Metab. 2014, 9, 61-72 10.1586/17446651.2014.862152
5. Manandhar, B.; Ahn, J.-M. Glucagon-like peptide-1 (GLP-1) analogs: Recent advances, new possibilities, and therapeutic implications J. Med. Chem. 2015, 58, 1020-1037 10.1021/jm500810s
6. Jones, R. M.; Leonard, J. N.; Buzard, D. J.; Lehmann, J. GPR119 agonists for the treatment of type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 1339-1359 10.1517/13543770903153878
7. Buzard, D. J.; Lehmann, J.; Han, S.; Jones, R. M. GPR119 agonists 2009-2011 Pharm. Pat. Anal. 2012, 1, 285-299 10.4155/ppa.12.33
8. Fyfe, M. C. T.; McCormack, J. G.; Overton, H. A.; Procter, M. J.; Reynet, C. GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity Expert Opin. Drug Discovery 2008, 3, 403-413 10.1517/17460441.3.4.403
9. Dhayal, S.; Morgan, N. G. The significance of GPR119 agonists as future treatment of type 2 diabetes Drugs News Perspect. 2010, 23, 418-424
10. Ohishi, T.; Yoshida, S. The therapeutic potential of GPR119 agonists for type 2 diabetes Expert Opin. Invest. Drugs 2012, 21, 321-328 10.1517/13543784.2012.657797
11. Shah, U.; Edmondson, S.; Szewczyk, J. W. Recent advances in the discovery of GPR119 agonists. In New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches; RSC Drug Discovery Series No. 27; Jones, R. M., Ed.; The Royal Society of Chemistry: London, 2012; pp 177-214.
12. Cornall, L. M.; Mathai, M. L.; Hryciw, D. H.; McAinch, A. J. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases? Expert Opin. Invest. Drugs 2013, 22, 487-498 10.1517/13543784.2013.775245
13. Kang, S.-U. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119 Drug Discovery Today 2013, 18, 1309-1324 10.1016/j.drudis.2013.09.011
14. Mo, X.-L.; Yang, Z.; Tao, Y.-X. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus Prog. Mol. Biol. Transl. Sci. 2014, 121, 95-131 10.1016/B978-0-12-800101-1.00004-1
15. Zhu, X.; Huang, W.; Qian, H. GPR119 agonists: A novel strategy for type 2 diabetes treatment. In Diabetes Mellitus-Insights and Perspectives; InTech: Rijeka, Croatia, 2013; pp 59-82, DOI: 10.5772/48444.
16. Polli, J. W.; Hussey, E.; Bush, M.; Generaux, G.; Smith, G.; Collins, D.; McMullen, S.; Turner, N.; Nunez, D. J. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design Xenobiotica 2013, 43, 498-508 10.3109/00498254.2012.739719
17. Nunez, D. J.; Bush, M. A.; Collins, D.; McMullen, S. L.; Gillmor, D.; Apseloff, G.; Atiee, G.; Corsino, L.; Morrow, L.; Feldman, P. L. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: Results from two randomized studies PLoS One 2014, 9, e92494 10.1371/journal.pone.0092494
18. Semple, G.; Ren, A.; Fioravanti, B.; Pereira, G.; Calderon, I.; Choi, K.; Xiong, Y.; Shin, Y.-J.; Gharbaoui, T.; Sage, C. R.; Morgan, M.; Xing, C.; Chu, Z.-L.; Leonard, J. N.; Grottick, A. J.; Al-Shamma, H.; Liang, Y.; Demarest, K. T.; Jones, R. M. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent model of glucose control Bioorg. Med. Chem. Lett. 2011, 21, 3134-3141 10.1016/j.bmcl.2011.03.007
19. Semple, G.; Lehmann, J.; Wong, A.; Ren, A.; Bruce, M.; Shin, Y.-J.; Sage, C. R.; Morgan, M.; Chen, W.-C.; Sebring, K.; Chu, Z.-L.; Leonard, J. N.; Al-Shamma, H.; Grottick, A. J.; Du, F.; Liang, Y.; Demarest, K.; Jones, R. M. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile Bioorg. Med. Chem. Lett. 2012, 22, 1750-1755 10.1016/j.bmcl.2011.12.092
20. Katz, L. B.; Gambale, J. J.; Rothenberg, P. L.; Vanapalli, S. R.; Vaccaro, N.; Xi, L.; Polidori, D. C.; Vets, E.; Sarich, T. C.; Stein, P. P. Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects Clin. Pharmacol. Ther. 2011, 90, 685-692 10.1038/clpt.2011.169
21. Katz, L. B.; Gambale, J. J.; Rothenberg, P. L.; Vanapalli, S. R.; Vaccaro, N.; Xi, L.; Sarich, T. C.; Stein, P. P. Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes Diabetes, Obes. Metab. 2012, 14, 709-716 10.1111/j.1463-1326.2012.01587.x
22. Wacker, D. A.; Wang, Y.; Broekema, M.; Rossi, K.; O'Connor, S.; Hong, Z.; Wu, G.; Malmstrom, S. E.; Hung, C.-P.; LaMarre, L.; Chimalakonda, A.; Zhang, L.; Xin, L.; Cai, H.; Chu, C.; Boehm, S.; Zalaznick, J.; Ponticiello, R.; Sereda, L.; Han, S.-P.; Zebo, R.; Zinker, B.; Luk, C. E.; Wong, R.; Everlof, G.; Li, Y.-X.; Wu, C. K.; Lee, M.; Griffen, S.; Miller, K. J.; Krupinski, J.; Robl, J. A. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119 J. Med. Chem. 2014, 57, 7499-7508 10.1021/jm501175v
23. He, Y.-L.; Zhang, Y.; Yan, J.-H.; Zhou, W.; Komjathy, S.; Taylor, A. High-quality triplicate electrocardiogram monitoring in a first-in-man study: Potential for early detection of drug-induced QT prolongation Int. J. Clin. Pharmacol. Ther. 2013, 51, 948-957 10.5414/CP201949
24. Overton, H. A.; Fyfe, M. C. T.; Reynet, C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity Br. J. Pharmacol. 2008, 153, S76-S81 10.1038/sj.bjp.0707529
25. Fredriksson, R.; Höglund, P. J.; Gloriam, D. E. I.; Lagerström, M. C.; Schiöth, H. B. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives FEBS Lett. 2003, 554, 381-388 10.1016/S0014-5793(03)01196-7
26. Odori, S.; Hosoda, K.; Tomita, T.; Fujikura, J.; Kusakabe, T.; Kawaguchi, Y.; Doi, R.; Takaori, K.; Ebihara, K.; Sakai, Y.; Uemoto, S.; Nakao, K. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function Metab., Clin. Exp. 2013, 62, 70-78 10.1016/j.metabol.2012.06.010
27. Little, T. J.; Isaacs, N. J.; Young, R. L.; Ott, R.; Nguyen, N. Q.; Rayner, C. K.; Horowitz, M.; Feinle-Bisset, C. Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index Am. J. Physiol.: Gastrointest. Liver Physiol. 2014, 307, G958-G967 10.1152/ajpgi.00134.2014
28. Chu, Z.-L.; Carroll, C.; Alfonso, J.; Gutierrez, V.; He, H.; Lucman, A.; Pedraza, M.; Mondala, H.; Gao, H.; Bagnol, D.; Chen, R.; Jones, R. M.; Behan, D. P.; Leonard, J. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release Endocrinology 2008, 149, 2038-2047 10.1210/en.2007-0966
29. Chu, Z.-L.; Jones, R. M.; He, H.; Carroll, C.; Gutierrez, V.; Lucman, A.; Moloney, M.; Gao, H.; Mondala, H.; Bagnol, D.; Unett, D.; Liang, Y.; Demarest, K.; Semple, G.; Behan, D. P.; Leonard, J. A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release Endocrinology 2007, 148, 2601-2609 10.1210/en.2006-1608
30. Soga, T.; Ohishi, T.; Matsui, T.; Saito, T.; Matsumoto, M.; Takasaki, J.; Matsumoto, S.; Kamohara, M.; Hiyama, H.; Yoshida, S.; Momose, K.; Ueda, Y.; Matsushime, H.; Kobori, M.; Furuichi, K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein coupled receptor Biochem. Biophys. Res. Commun. 2005, 326, 744-751 10.1016/j.bbrc.2004.11.120
31. Overton, H. A.; Babbs, A. J.; Doel, S. M.; Fyfe, M. C. T.; Gardner, L. S.; Griffin, G.; Jackson, H. C.; Procter, M. J.; Rasamison, C. M.; Tang-Christensen, M.; Widdowson, P. S.; Williams, G. M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab. 2006, 3, 167-175 10.1016/j.cmet.2006.02.004
32. Chu, Z.-L.; Carroll, C.; Chen, R.; Alfonso, J.; Gutierrez, V.; He, H.; Lucman, A.; Xing, C.; Sebring, K.; Zhou, J.; Wagner, B.; Unett, D.; Jones, R. M.; Behan, D. P.; Leonard, J. N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119 Mol. Endocrinol. 2010, 24, 161-170 10.1210/me.2009-0239
33. Syed, S. K.; Bui, H. H.; Beavers, L. S.; Farb, T. B.; Ficorilli, J.; Chesterfield, A. K.; Kuo, M.-S.; Bokvist, K.; Barrett, D. G.; Efanov, A. M. Regulation of GPR119 receptor activity with endocannabinoid-like lipids Am. J. Physiol.: Endocrinol. Metabol. 2012, 303, E1469-E1478 10.1152/ajpendo.00269.2012
34. Hansen, H. S.; Rosenkilde, M. M.; Holst, J. J.; Schwartz, T. W. GPR119 as a fat sensor Trends Pharmacol. Sci. 2012, 33, 374-381 10.1016/j.tips.2012.03.014
35. Moran, B. M.; Abdel-Wahab, Y. H. A.; Flatt, P. R.; McKillop, A. M. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice Biol. Chem. 2014, 395, 453-464 10.1515/hsz-2013-0255
36. Kleberg, K.; Hassing, H. A.; Hansen, H. S. Classical endocannabinoid-like compounds and their regulation by nutrients BioFactors 2014, 40, 363-372 10.1002/biof.1158
37. Zhu, X.; Huang, D.; Lan, X.; Tang, C.; Zhu, Y.; Han, J.; Huang, W.; Qian, H. The first pharmacophore model for potent G protein-coupled receptor 119 agonist Eur. J. Med. Chem. 2011, 46, 2901-2907 10.1016/j.ejmech.2011.04.014
38. Semple, G.; Fioravanti, B.; Pereira, G.; Calderon, I.; Uy, J.; Choi, K.; Xiong, Y.; Ren, A.; Morgan, M.; Dave, V.; Thomsen, W.; Unett, D. J.; Xing, C.; Bossie, S.; Carroll, C.; Chu, Z.-L.; Grottick, A. J.; Hauser, E. K.; Leonard, J.; Jones, R. M. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119 J. Med. Chem. 2008, 51, 5172-5175 10.1021/jm8006867
39. Buzard, D. J.; Kim, S. H.; Lehmann, J.; Han, S.; Calderon, I.; Wong, A.; Kawasaki, A.; Narayanan, S.; Bhat, R.; Gharbaoui, T.; Lopez, L.; Yue, D.; Whelan, K.; Al-Shamma, H.; Unett, D. J.; Shu, H.-H.; Tung, S.-F.; Chang, S.; Chuang, C.-F.; Morgan, M.; Sadeque, A.; Chu, Z.-L.; Leonard, J.; Jones, R. M. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 4332-4335 10.1016/j.bmcl.2014.06.071
40. Katamreddy, S. R.; Carpenter, A. J.; Ammala, C. E.; Boros, E. E.; Brashear, R. L.; Briscoe, C. P.; Bullard, S. R.; Caldwell, R. D.; Conlee, C. R.; Croom, D. K.; Hart, S. M.; Heyer, D. O.; Johnson, P. R.; Kashatus, J. A.; Minick, D. J.; Peckham, G. E.; Ross, S. A.; Roller, S. G.; Samano, V. A.; Sauls, H. R.; Tadepalli, S. M.; Thompson, J. B.; Xu, Y.; Way, J. M. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists J. Med. Chem. 2012, 55, 10972-10994 10.1021/jm301404a
41. Gillespie, P.; Goodnow, R. A., Jr.; Saha, G.; Bose, G.; Moulik, K.; Zwingelstein, C.; Myers, M.; Conde-Knape, K.; Pietranico-Cole, S.; So, S.-S. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 949-953 10.1016/j.bmcl.2013.12.063
42. Fevig, J. M.; Wacker, D. A. [6,5]-Bicyclic GPR119 G protein-coupled receptor agonists. WO 2008/137436, 2008.
43. Fevig, J. M.; Wacker, D. A. [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists. WO 2008/137435, 2008.
44. Neelamkavil, S. F.; Boyle, C. D.; Harris, J. M.; Stamford, A. W.; Hao, J.; Neustadt, B. R.; Chackalamannil, S.; Xia, Y.; Greenlee, W. J. Bicyclic heterocycle derivatives and their use as GPCR modulators. WO 2010/009207, 2010.
45. Sato, K.; Sugimoto, H.; Rikimaru, K.; Imoto, H.; Kamaura, M.; Negoro, N.; Tsujihata, Y.; Miyashita, H.; Odani, T.; Murata, T. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists Bioorg. Med. Chem. 2014, 22, 1649-1666 10.1016/j.bmc.2014.01.028
46. McClure, K. F.; Darout, E.; Guimarães, C. R. W.; DeNinno, M. P.; Mascitti, V.; Munchhof, M. J.; Robinson, R. P.; Kohrt, J.; Harris, A. R.; Moore, D. E.; Li, B.; Samp, L.; Lefker, B. A.; Futatsugi, K.; Kung, D.; Bonin, P. D.; Cornelius, P.; Wang, R.; Salter, E.; Hornby, S.; Kalgutkar, A. S.; Chen, Y. Activation of the G-protein-coupled receptor 119: A conformation-based hypothesis for understanding agonist response J. Med. Chem. 2011, 54, 1948-1952 10.1021/jm200003p
47. Darout, E.; Robinson, R. P.; McClure, K. F.; Corbett, M.; Li, B.; Shavnya, A.; Andrews, M. P.; Jones, C. S.; Li, Q.; Minich, M. L.; Mascitti, V.; Guimarães, C. R. W.; Munchhof, M. J.; Bahnck, K. B.; Cai, C.; Price, D. A.; Liras, S.; Bonin, P. D.; Cornelius, P.; Wang, R.; Bagdasarian, V.; Sobota, C. P.; Hornby, S.; Masterson, V. M.; Joseph, R. M.; Kalgutkar, A. S.; Chen, Y. Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119 J. Med. Chem. 2013, 56, 301-319 10.1021/jm301626p
48. Xia, Y.; Chackalamannil, S.; Greenlee, W. J.; Jayne, C.; Neustadt, B.; Stamford, A.; Vaccaro, H.; Xu, X.; Baker, H.; O'Neill, K.; Woods, M.; Hawes, B.; Kowalski, T. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes Bioorg. Med. Chem. Lett. 2011, 21, 3290-3296 10.1016/j.bmcl.2011.04.035
49. Pham, T.-A. N.; Yang, Z.; Fang, Y.; Luo, J.; Lee, J.; Park, H. Synthesis and biological evaluation of novel 2,4-disubstituted quinazoline analogues as GPR119 agonists Bioorg. Med. Chem. 2013, 21, 1349-1356 10.1016/j.bmc.2012.12.013
50. Yang, Z.; Fang, Y.; Pham, T.-A. N.; Lee, J.; Park, H. Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists Bioorg. Med. Chem. Lett. 2013, 23, 1519-1521 10.1016/j.bmcl.2012.12.011
51. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Broo, A.; Brown, H. S.; Butlin, R. J.; Clarke, D. S.; Davidsson, Ö.; Ertan, A.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Laber, D.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Pickup, A.; Schofield, P.; Svensson, P. H.; Sörme, P.; Teague, J. Use of small-molecule crystal structures to address solubility in a novel series of G protein-coupled receptor 119 agonists: Optimization of a lead and in vivo evaluation J. Med. Chem. 2012, 55, 5361-5379 10.1021/jm300310c
52. Brocklehurst, K. J.; Broo, A.; Butlin, R. J.; Brown, H. S.; Clarke, D. S.; Davidsson, Ö.; Goldberg, K.; Groombridge, S. D.; Kelly, E. E.; Leach, A.; McKerrecher, D.; O'Donnell, C.; Poucher, S.; Schofield, P.; Scott, J. S.; Teague, J.; Westgate, L.; Wood, M. J. M. Discovery, optimization and in vivo evaluation of novel GPR119 agonists Bioorg. Med. Chem. Lett. 2011, 21, 7310-7316 10.1016/j.bmcl.2011.10.033
53. Scott, J. S.; Bowker, S. S.; Brocklehurst, K. J.; Brown, H. S.; Clarke, D. S.; Easter, A.; Ertan, A.; Goldberg, K.; Hudson, J. A.; Kavanagh, S.; Laber, D.; Leach, A. G.; MacFaul, P. A.; Martin, M. A.; McKerrecher, D.; Schofield, P.; Svensson, P. H.; Teague, J. Circumventing seizure activity in a series of G protein-coupled receptor 119 (GPR119) agonists J. Med. Chem. 2014, 57, 8984-8998 10.1021/jm5011012
54. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Brown, H. S.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Poultney, R.; Schofield, P.; Svensson, P. H. Optimisation of aqueous solubility in a series of G protein-coupled receptor 119 (GPR119) agonists MedChemComm 2013, 4, 95-100 10.1039/C2MD20130E
55. Scott, J. S.; Brocklehurst, K. J.; Brown, H. S.; Clarke, D. S.; Coe, H.; Groombridge, S. D.; Laber, D.; MacFaul, P. A.; McKerrecher, D.; Schofield, P. Conformational restriction in a series of GPR119 agonists: Differences in pharmacology between mouse and human Bioorg. Med. Chem. Lett. 2013, 23, 3175-3179 10.1016/j.bmcl.2013.04.006
56. Sakairi, M.; Kogami, M.; Torii, M.; Kataoka, H.; Fujieda, H.; Makino, M.; Kataoka, D.; Okamoto, R.; Miyazawa, T.; Okabe, M.; Inoue, M.; Takahashi, N.; Harada, S.; Watanabe, N. Synthesis and SAR studies of bicyclic amine series GPR119 agonists Bioorg. Med. Chem. Lett. 2012, 22, 5123-5128 10.1016/j.bmcl.2012.05.117
57. Sakairi, M.; Kogami, M.; Torii, M.; Kuno, Y.; Ohsawa, Y.; Makino, M.; Kataoka, D.; Okamoto, R.; Miyazawa, T.; Inoue, M.; Takahashi, N.; Harada, S.; Watanabe, N. Synthesis and biological evaluation of a 6-aminofuro[3,2-c]pyridin-3(2H)-one series of GPR 119 agonists Arzneim. Forsch. 2012, 62, 537-544 10.1055/s-0032-1323760
58. Sakairi, M.; Kogami, M.; Torii, M.; Makino, M.; Kataoka, D.; Okamoto, R.; Miyazawa, T.; Inoue, M.; Takahashi, N.; Harada, S.; Watanabe, N. Synthesis and pharmacological profile of a new selective G protein-coupled receptor 119 agonist; 6-((2-fluoro-3-(1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)propyl)amino)-2,3-dihydro-1H-inden-1-one Chem. Pharm. Bull. 2012, 60, 1093-1095 10.1248/cpb.c12-00484
59. Wellenzohn, B.; Lessel, U.; Beller, A.; Isambert, T.; Hoenke, C.; Nosse, B. Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry J. Med. Chem. 2012, 55, 11031-11041 10.1021/jm301549a
60. Ye, X.-Y.; Morales, C. L.; Wang, Y.; Rossi, K. A.; Malmstrom, S. E.; Abousleiman, M.; Sereda, L.; Apedo, A.; Robl, J. A.; Miller, K. J.; Krupinski, J.; Wacker, D. A. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 2539-2545 10.1016/j.bmcl.2014.03.096
61. Koshizawa, T.; Hosoi, H.; Watanabe, G.; Morimoto, T.; Ohgiya, T.; Shibuya, K. A practical synthesis of (4-(spiro[chromane-2,4′-piperidin]-6-yl)phenyl)methanol as a key intermediate of novel GPR119 agonist Heterocycles 2014, 89, 1632-1643 10.3987/COM-14-13012
62. Koshizawa, T.; Yamazaki, Y.; Ohgiya, T.; Shibuya, K. A facile method for converting alcohol to thioether and its application in the synthesis of a novel GPR119 agonist Tetrahedron 2015, 71, 3231-3236 10.1016/j.tet.2015.04.002
63. Szewczyk, J. W.; Acton, J.; Adams, A. D.; Chicchi, G.; Freeman, S.; Howard, A. D.; Huang, Y.; Li, C.; Meinke, P. T.; Mosely, R.; Murphy, E.; Samuel, R.; Santini, C.; Yang, M.; Zhang, Y.; Zhao, K.; Wood, H. B. Design of potent and selective GPR119 agonists for type II diabetes Bioorg. Med. Chem. Lett. 2011, 21, 2665-2669 10.1016/j.bmcl.2010.12.086
64. Lohani, S.; Cooper, H.; Jin, X.; Nissley, B. P.; Manser, K.; Rakes, L. H.; Cummings, J. J.; Fauty, S. E.; Bak, A. Physicochemical properties, form, and formulation selection strategy for a biopharmaceutical classification system class II preclinical drug candidate J. Pharm. Sci. 2014, 103, 3007-3021 10.1002/jps.24088
65. Leung, D. H.; Lohani, S.; Ball, R. G.; Canfield, N.; Wang, Y.; Rhodes, T.; Bak, A. Two novel pharmaceutical cocrystals of a development compound-screening, scale-up, and characterization Cryst. Growth Des. 2012, 12, 1254-1262 10.1021/cg201270s
66. Leung, D. H.; Lamberto, D. J.; Liu, L.; Kwong, E.; Nelson, T.; Rhodes, T.; Bak, A. A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology Int. J. Pharm. 2014, 473, 10-19 10.1016/j.ijpharm.2014.05.003
67. Liu, P.; Hu, Z.; DuBois, B. G.; Moyes, C. R.; Hunter, D. N.; Zhu, C.; Kar, N. F.; Zhu, Y.; Garfunkle, J.; Kang, L.; Chicchi, G.; Ehrhardt, A.; Woods, A.; Seo, T.; Woods, M.; van Heek, M.; Dingley, K. H.; Pang, J.; Salituro, G. M.; Powell, J.; Terebetski, J. L.; Hornak, V.; Campeau, L.-C.; Lamberson, J.; Ujjainwalla, F.; Miller, M.; Stamford, A.; Wood, H. B.; Kowalski, T.; Nargund, R. P.; Edmondson, S. D. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes ACS Med. Chem. Lett. 2015, 6, 936-941 10.1021/acsmedchemlett.5b00207
68. Han, S.; Narayanan, S.; Kim, S. H.; Calderon, I.; Zhu, X.; Kawasaki, A.; Yue, D.; Lehmann, J.; Wong, A.; Buzard, D. J.; Semple, G.; Carroll, C.; Chu, Z.-L.; Al-Sharmma, H.; Shu, H.-H.; Tung, S.-F.; Unett, D. J.; Behan, D. P.; Yoon, W. Y.; Morgan, M.; Usmani, K. W.; Chen, C.; Sadeque, A.; Leonard, J. N.; Jones, R. M. Discovery of novel trans-1,4-dioxycyclo-hexane GPR119 agonist series Bioorg. Med. Chem. Lett. 2015, 25, 3034-3038 10.1016/j.bmcl.2015.04.102
69. Futatsugi, K.; Mascitti, V.; Guimarães, C. R. W.; Morishita, N.; Cai, C.; DeNinno, M. P.; Gao, H.; Hamilton, M. D.; Hank, R.; Harris, A. R.; Kung, D. W.; Lavergne, S. Y.; Lefker, B. A.; Lopaze, M. G.; McClure, K. F.; Munchhof, M. J.; Preville, C.; Robinson, R. P.; Wright, S. W.; Bonin, P. D.; Cornelius, P.; Chen, Y.; Kalgutkar, A. S. From partial to full agonism: Identification of a novel 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole as a full agonist of the human GPR119 receptor Bioorg. Med. Chem. Lett. 2013, 23, 194-197 10.1016/j.bmcl.2012.10.119
70. Yoshida, S.; Ohishi, T.; Matsui, T.; Shibasaki, M. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion Biochem. Biophys. Res. Commun. 2010, 400, 437-441 10.1016/j.bbrc.2010.08.097
71. Negoro, K.; Yonetoku, Y.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure-activity relationship of 4-amino-2-phenylpyrimidine derivatives as a series of novel GPR119 agonists Bioorg. Med. Chem. 2012, 20, 2369-2375 10.1016/j.bmc.2012.02.006
72. Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Oshima, H.; Yonetoku, Y.; Shibasaki, M. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice Biochem. Biophys. Res. Commun. 2010, 402, 280-285 10.1016/j.bbrc.2010.10.015
73. Oshima, H.; Yoshida, S.; Ohishi, T.; Matsui, T.; Tanaka, H.; Yonetoku, Y.; Shibasaki, M.; Uchiyama, Y. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice Life Sci. 2013, 92, 167-173 10.1016/j.lfs.2012.11.015
74. Negoro, K.; Yonetoku, Y.; Misawa-Mukai, H.; Hamaguchi, W.; Maruyama, T.; Yoshida, S.; Takeuchi, M.; Ohta, M. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists Bioorg. Med. Chem. 2012, 20, 5235-5246 10.1016/j.bmc.2012.06.049
75. Negoro, K.; Yonetoku, Y.; Moritomo, A.; Hayakawa, M.; Iikubo, K.; Yoshida, S.; Takeuchi, M.; Ohta, M. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists Bioorg. Med. Chem. 2012, 20, 6442-6451 10.1016/j.bmc.2012.08.054
76. Zhang, J.; Li, A.-R.; Yu, M.; Wang, Y.; Zhu, J.; Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Eksterowicz, J.; Coward, P.; Liu, J. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists Bioorg. Med. Chem. Lett. 2013, 23, 3609-3613 10.1016/j.bmcl.2013.04.014
77. Wang, Y.; Yu, M.; Zhu, J.; Zhang, J.; Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Liu, J.; Coward, P. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 1133-1137 10.1016/j.bmcl.2013.12.127
78. Yu, M.; Zhang, J.; Wang, Y.; Zhu, J.; Kayser, F.; Medina, J. C.; Siegler, K.; Conn, M.; Shan, B.; Grillo, M. P.; Coward, P.; Liu, J. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 156-160 10.1016/j.bmcl.2013.11.053
79. Mascitti, V.; Stevens, B. D.; Choi, C.; McClure, K. F.; Guimarães, C. R. W.; Farley, K. A.; Munchhof, M. J.; Robinson, R. P.; Futatsugi, K.; Lavergne, S. Y.; Lefker, B. A.; Cornelius, P.; Bonin, P. D.; Kalgutkar, A. S.; Sharma, R.; Chen, Y. Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor Bioorg. Med. Chem. Lett. 2011, 21, 1306-1309 10.1016/j.bmcl.2011.01.088
80. Alper, P.; Azimioara, M.; Cow, C.; Mutnick, D.; Nikulin, V.; Michellys, P.-Y.; Wang, Z.; Reding, E.; Paliotti, M.; Li, J.; Bao, D.; Zoll, J.; Kim, Y.; Zimmerman, M.; Groessel, T.; Tuntland, T.; Joseph, S. B.; McNamara, P.; Seidel, H. M.; Epple, R. Discovery of structurally novel, potent and orally efficacious GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 2383-2387 10.1016/j.bmcl.2014.03.023
81. Azimioara, M.; Alper, P.; Cow, C.; Mutnick, D.; Nikulin, V.; Lelais, G.; Mecom, J.; McNeill, M.; Michellys, P.-Y.; Wang, Z.; Reding, E.; Paliotti, M.; Li, J.; Bao, D.; Zoll, J.; Kim, Y.; Zimmerman, M.; Groessl, T.; Tuntland, T.; Joseph, S. B.; McNamara, P.; Seidel, H. M.; Epple, R. Novel tricyclic pyrazalopyrimidines as potent and selective GPR119 agonists Bioorg. Med. Chem. Lett. 2014, 24, 5478-5483 10.1016/j.bmcl.2014.10.010